Simvastatin
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Simvastatin: From Hypercholesterolemia to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is an HMG-CoA reductase inhibitor originally used to lower LDL-cholesterol in general hypercholesterolemia and mixed dyslipidemia. The TxGNN model predicts it may also be effective for Familial Hypercholesterolemia (FH), with 19 clinical trials and 18 publications currently supporting this direction — though, as noted below, this largely confirms an already-approved statin-class indication rather than a novel repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the evidence pack's Norway license data (0 licenses on file); simvastatin is internationally indicated for hypercholesterolemia and mixed dyslipidemia |
| Predicted New Indication | Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Formal mechanism-of-action documentation (the DrugBank MOA field) is currently a data gap for this candidate. However, the evidence pack's own repurposing rationale supplies the mechanism: simvastatin is an HMG-CoA reductase inhibitor that blocks the rate-limiting step of hepatic cholesterol biosynthesis, thereby lowering LDL-C synthesis and up-regulating LDL receptor expression.
Familial hypercholesterolemia is caused by defective LDL receptor function, producing markedly elevated LDL-C from birth. Because statins directly counteract this pathway, the mechanistic fit is strong and well established — this is reflected in the large volume of Phase 3 evidence below, much of it using simvastatin as either the primary study drug or the standard background therapy.
Importantly, the evidence pack's rationale explicitly flags that this is not a novel repurposing discovery: statins, including simvastatin, are already an approved treatment class for FH. TxGNN's high score here reflects recovery of known, guideline-endorsed pharmacology rather than an unexpected new therapeutic area. This should be factored into how much additional strategic value this candidate carries versus the lower-ranked, evidence-free predictions (e.g., brain stem infarction, CETP deficiency) also present in this pack.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02107898 | Phase 3 | Completed | 216 | Alirocumab add-on to stable statin therapy (incl. simvastatin) vs placebo; LDL-C reduction in heterozygous FH |
| NCT03885921 | Phase 3 | Completed | 44 | 24-month open-label extension: long-term safety of ezetimibe + atorvastatin/simvastatin in homozygous FH |
| NCT00654446 | Phase 3b | Completed | 442 | Renal effects of rosuvastatin vs simvastatin in Fredrickson type IIa/IIb dyslipidemia incl. heterozygous FH |
| NCT01507831 | Phase 3 | Completed | 2341 | Long-term safety/tolerability of alirocumab vs placebo in high-CV-risk hypercholesterolemia on background statin therapy |
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone; carotid atherosclerosis progression in heterozygous FH |
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe co-administered with atorvastatin or simvastatin in homozygous FH; efficacy and safety |
| NCT00129402 | Phase 3 | Completed | 248 | Ezetimibe + simvastatin vs simvastatin alone in adolescents (10–17y) with heterozygous FH |
| NCT01070966 | N/A (post-marketing) | Completed | 2089 | Re-examination/surveillance study of VYTORIN (ezetimibe/simvastatin) safety and efficacy in routine practice |
| NCT01890967 | Phase 2 | Completed | 527 | Dose-ranging study of LY3015014 (PCSK9 antibody) added to background statin (incl. simvastatin) ± ezetimibe |
| NCT01623115 | Phase 3 | Completed | 486 | Alirocumab vs placebo in heterozygous FH inadequately controlled on lipid-modifying therapy (statin background) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41824552 | 2026 | Guideline | Circulation | New ACC/AHA dyslipidemia guideline replacing the 2018 cholesterol guideline; reaffirms statin-based lipid management framework relevant to FH |
| 18376000 | 2008 | RCT | New England Journal of Medicine | ENHANCE trial: ezetimibe + simvastatin vs simvastatin alone in heterozygous FH; greater LDL-C lowering without additional carotid IMT benefit |
| 31696945 | 2019 | Systematic Review (Cochrane) | Cochrane Database of Systematic Reviews | Statins, including simvastatin, safely and effectively reduce LDL-C in pediatric FH patients |
| 15794711 | 2005 | Review | Expert Opinion on Drug Safety | Benefit-risk assessment of simvastatin specifically in familial hypercholesterolemia; supports long-term use |
| 27417002 | 2016 | Cohort | Journal of the American College of Cardiology | Statin therapy associated with reduced coronary artery disease events and all-cause mortality in FH |
| 12908847 | 2003 | Review | Drug Safety | Long-term benefits and risks of simvastatin in familial hypercholesterolemia patients |
| 21173733 | 2010 | Cohort | International Angiology | Long-term ezetimibe/simvastatin treatment reduces CV risk markers in FH |
| 28437620 | 2017 | Guideline | Endocrine Practice (AACE/ACE) | Dyslipidemia management guideline recommending statin-based therapy including for FH |
| 11383320 | 2001 | RCT | Nutrition, Metabolism & Cardiovascular Diseases | Atorvastatin vs simvastatin comparison for LDL-C goal attainment in heterozygous FH |
| 35629051 | 2022 | Cross-sectional | Journal of Clinical Medicine | Immune parameters in pediatric FH patients on simvastatin show no adverse immunological effects |
Norway Market Information
Simvastatin currently has 0 registered authorizations in the Norway regulatory data provided (market_status: 未上市, not marketed). No product/authorization records are available to list.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data are not yet available in this evidence pack (see Data Gaps below).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Evidence strength is high (L1: multiple completed Phase 3 RCTs directly involving simvastatin in FH populations), but the pack's own rationale confirms this is essentially validation of an already-approved statin-class indication rather than a novel repurposing opportunity. Combined with the drug's current unmarketed status in Norway and missing label-level safety data, guardrails are warranted before any regulatory or commercial action.
To proceed, the following is needed:
- TFDA/Norway product label warnings and contraindications (Blocking gap — required before safety pre-assessment, per data_gaps DG001)
- Formal DrugBank mechanism-of-action record (High priority gap DG002, to replace the inferred MOA used in this report)
- Clarification of Norway market-entry pathway, since simvastatin currently has zero registered authorizations
- Strategic reassessment of whether this candidate merits prioritization given it largely reconfirms known statin pharmacology, versus the lower-ranked, evidence-free predictions in this pack (e.g., brain stem infarction, CETP deficiency) that would represent genuinely novel signals if evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.